U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H41NO6S
Molecular Weight 507.683
Optical Activity ( - )
Defined Stereocenters 7 / 7
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PATUPILONE

SMILES

C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C3=CSC(C)=N3

InChI

InChIKey=QXRSDHAAWVKZLJ-PVYNADRNSA-N
InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H41NO6S
Molecular Weight 507.683
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 1
Optical Activity UNSPECIFIED

Description

Patupilone is a compound isolated from the myxobacterium Sorangium cellulosum. Similar to paclitaxel, Patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions. In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes. Epothilone B may cause complete cell-cycle arrest. Patupilone failed a phase III trial for ovarian cancer in 2010.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
4.7 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
139 ng/mL
11 mg/m² single, intravenous
PATUPILONE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1386 ng × h/mL
11 mg/m² single, intravenous
PATUPILONE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
100 h
11 mg/m² single, intravenous
PATUPILONE plasma
Homo sapiens

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Patupilone (Novartis, Basel, Switzerland) was administered every 3 weeks either as a bolus (20 min), 1-day continuous infusion (24 h) or 5-day continuous infusion (16-h per day over 5 days) at dose levels of 6.5, 7.0, 7.5, 8.0, 9.0 and 10.0 mg/m2 until disease progression, unacceptable toxicity or withdrawal of consent.
Route of Administration: Intravenous
In Vitro Use Guide
Cortices were dissected from embryonic 15.5mice and incubated in papain (20U/mL, Worthington) containing DNase (10 U/𝜇L, Sigma) for 40min at 37∘C. Enzyme-digested cortices were washed three times with MEM (Cellgro) containing 10% heat inactivated fetal bovine serum (Hyclone) and dissociated in culture medium. Dissociated neurons were then centrifuged to remove the supernatant and counted cells were plated on glass coverslips coated with 100 𝜇g/mL poly-D-lysine (Sigma) and grown in Neurobasal A (Gibco) medium containing Glutamax (1%, Thermo Fisher Scientific) and B27 (2%, Thermo Fisher Scientific) supplements. 5 hr after plating, neurons were treated with epothilone B (from 1 pM to 1 𝜇M and 10pM or 1 nM) for 3 days in low-density cultures (5 x 104 cells in 1.9 cm2) or overnight (17–19hr) in high-density cultures (2 x 105 cells in 1.9 cm2). Neurons were then fixed and analyzed for viability, axon growth, and microtubule structure.
Substance Class Chemical
Record UNII
UEC0H0URSE
Record Status Validated (UNII)
Record Version